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Public, private and non-specific antibodies induced by
non-cytopathic viral infections
Mike Recher1, Lukas Hunziker2, Adrian Ciurea3, Nicola Harris1 and
Karl S Lang1Lymphocytic choriomeningitis virus (LCMV) represents a useful
experimental model of murine infection with a non-cytopathic
virus, bearing resemblance to HIV and hepatitis C virus (HCV)
infections in humans. Recent data from the LCMV model
indicate that the humoral immune response that is induced by
non-cytopathic viruses is far more complex than previously
appreciated. LCMV-induced IgG production is largely
polyclonal, with more than 90% of the antibody repertoire
constituting non-relevant specificities. A delayed virus-
neutralizing antibody response is induced, including
specificities directed not only against the parental LCMV-strain
present in the host but also cross-specifically against LCMV-
variants isolated from other hosts. These findings provide novel
insights to aid our understanding of clinically relevant
observations that are recorded following human infection with
HIV, HCV and dengue viruses.
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proteinIntroduction
Viruses can be broadly divided into those that are cyto-
pathic to the host and those that are poorly or non-
cytopathic. Cytopathic viruses — including poliovirus
and vesicular stomatitis virus (VSV) — interfere with
essential cellular processes, ultimately resulting in cellu-Opinion in Microbiology 2004, 7:426–433lar death, and are capable of killing the host if the immune
response cannot control viral replication in a timely
fashion. This normally necessitates the rapid production
of neutralizing antibodies because, although effective,
cytolytic CD8+ T cell responses normally occur too late
to prevent viral spread [1,2]. Cytopathic viruses are often
classified into relatively few serotypes according to the
specificity of the host’s antibody response for surface
glycoprotein antigens. However, it is now clear that such
definitions are overly simplistic in light of the finding that
a greater genetic variability often exists at other loci
within the viral genome [3,4].
Poorly or non-cytopathic viruses, including murine lym-
phocytic choriomeningitis virus (LCMV), hepatitis C
virus (HCV), HIV and also dengue virus, have evolved
to replicate within host cells without interfering with
those processes that are essential for cellular survival
[5–7]. Instead, disease is largely caused by the host’s
own immune response, including CTL (cytotoxic lym-
phocyte)-mediated lysis of virus-infected cells [8] and
chronic immune activation [9,10]. Clearance of poorly or
non-cytopathic viruses is usually mediated by CD8+ T
cells, and is reliant upon the gain of lytic function by these
cells, as demonstrated by the importance of molecules
such as perforin [11], granzymes [12] and Fas ligand [13].
Yet many poorly or non-cytopathic viruses tend to persist,
either as a consequence of their localisation in the per-
iphery, as a consequence of the formation of CTL-escape
viral mutants or as a result of viral-induced exhaustion of
the CTL response [14–16]. Neutralizing antibodies,
which are crucial for protection against cytopathic viruses,
are usually detectable only at late time-points after infec-
tion with poorly or non-cytopathic viruses and are more
prominent in situations of CD8+ T-cell non-responsive-
ness [17,18,19,20]. Nevertheless, should a poorly or non-
cytopathic virus manage to escape CTL attack, the sub-
sequent neutralizing antibody response becomes crucial
for viral control. This can be demonstrated by the isola-
tion of neutralizing antibody viral escape mutants at late
time-points after infection of CD8/ mice [21–23].
Poorly or non-cytopathic RNA viruses are normally
classified into different biological strains, genetic sub-
types or genetic clades [24–26]. Importantly, replicating
virus within one host should be regarded as a so-called
‘quasispecies’, reflecting a dynamic set of genetically
distinct viral subtypes [27,28]. As a general rule, a greater
number of viral serotypes can be distinguished for poorlywww.sciencedirect.com
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however, correlations between genetic subtypes, biologi-
cal behaviour and neutralizing serotypes remain equivo-
cal [29].
Neutralizing antibody-escape variants
Despite their late appearance, neutralizing antibodies
represent a very effective means of controlling persistent
infections with poorly or non-cytopathic viruses. Indeed,
studies of simian immunodeficiency virus (SIV) infection
in macaques or LCMV infection of mice have demon-
strated that the passive transfer of monoclonal neutraliz-
ing antibody before viral infection results in rapid viral
clearance and protection from a productive infection
[30,31]. Neutralizing antibodies can also act to prevent
CTL exhaustion and the emergence of CTL-escape
variants, by virtue of their ability to limit viral replication
[32,33]. The formation of neutralizing antibody-escape
variants can be demonstrated by the ability of the host
serum to neutralize the parental viral strain (used to
inoculate the host) but not virus recovered from the host
at later time-points [21]. This finding presents a great
concern for clinical diagnosis of chronic viral infections;
most current technologies use monoclonal antibodies
directed against the parental viral strain for viral detec-
tion, and therefore do not account for the possible emer-
gence of antibody-escape variants [34].
The emergence of neutralizing antibody-escape variants
has been most widely studied in LCMV infection of
murine hosts. Using this model, experiments can be
performed in which pressure on the virus to develop
neutralizing antibody-escape variants is enhanced
through infection of CD8/ mice [21]. These mice
exhibit a high initial rate of LCMV replication as a
consequence of the absent CTL response; however,
between days 40–60 post-infection, neutralizing antibo-
dies are generated and blood virus titers drop, indicating
viral control. In these mice, pressure on the virus toFigure 1
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The in vivo generation of LCMV neutralizing antibody-escape mutants in CD
www.sciencedirect.comdevelop escape mutants is mainly provided by the neu-
tralizing antibody response and not by CTL activity
(because CD8+ T cells are missing). Accordingly, by
day 80 post-infection, neutralizing antibody-escape var-
iants can be subcloned from the blood of CD8/ mice,
and these correlate with viral re-emergence (Figure 1).
Such antibody-escape variants have been shown to pos-
sess acquired amino acid substitutions, clustered within
three distinct regions of the surface glycoprotein, sugges-
tive of a tertiary LCMV-glycoprotein structure in which
these three regions combine to form one conformational
antibody epitope [21]. However, this hypothesis awaits
formal confirmation by the crystallization of the LCMV-
glycoprotein. Recent evidence demonstrates that HIV
uses similar strategies in vivo to escape the pressure of
neutralizing antibodies [35]. Here, mutations primarily
involved changes in N-linked glycosylation, suggesting a
‘glycan shield’ mechanism of neutralization escape,
whereby selected changes in glycan packing prevent
antibody but not receptor binding [35].
Public and private antibody specificities
Neutralizing-escape viral variants can be isolated from
CD8/ hosts, subcloned and used for infection of new
hosts. In this situation, the new host invariably develops a
neutralizing antibody response against the variant glyco-
protein and the virus is usually controlled in a manner
similar to the control of the wild-type variant in its original
host — possibly resulting in the generation of further
escape variants [21,36]. This suggests that, within the
original host, a given viral escape mutant does not manage
to escape the genetically possible B cell repertoire, but
only the current neutralizing antibody response. Should a
new host be infected with a neutralizing-escape variant,
subcloned from a carrier mouse, the new host generates
antibodies that not only exhibit neutralizing activity
against the escape variant that was used for inoculation,
but also against the parental virus (which this host has
never seen). This cross-specific antibody response is antibody titer
tion
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Neutralizing antibody-escape mutants can also be induced in some inbred CD8+ T-cell-competent mice, if high viral doses of LCMV (strain WE)
are used. In contrast to CD8/ mice, neutralizing-escape mutants are only induced in 75% of the cases. In mice with long-term controlled LCMV,
serum activity has a broader cross-neutralizing activity (tested against virus-escape mutants arising in other mice) than in mice where virus
re-emerges. Together, cross-specific neutralizing antibodies define a more ‘public’ or general neutralizing serotype. By contrast, neutralizing
activity of a host that is specific for the inoculated strain defines the ‘private’ serotype (adapted from [36]).usually of a lower titer and reflects a more ‘general’ or
‘public’ response. By contrast, the initial neutralizing
antibody response against the inoculated strain is of a
high-titer and reflects a more private antibody specificity
(Figure 2). Public cross-reactive antibody specificities
have also been described recently for HIV [37].
Although all CD8/ mice develop a ‘carrier’ status
following LCMV infection, a proportion of DBA/2 mice
(which are CTL-competent, see later) that are infected
with parental virus do not allow the development of
neutralizing antibody-escape-variants (Figure 2). These
mice invariably generate an antibody response that exhi-
bits some neutralizing activity, directed not only against
the parental virus, but also against viral strains isolated
from littermates in whom neutralizing-escape variants did
emerge. This cross-neutralizing response, reflecting pub-
lic specificity, was typically lower in DBA/2 mice, whereCurrent Opinion in Microbiology 2004, 7:426–433escape variants emerged, indicating a crucial role of
public specificities in long-term virus control. One pos-
sible explanation for this phenomenon is that, in a portion
of LCMV infected hosts, the rapidly replicating virus
acquires mutations and generates an array of quasi-spe-
cies over time, with each new clone inducing a specific
neutralizing antibody response. This possibility is sup-
ported by the observation that viral polymerases act in an
error-prone manner, due to the absence of fidelity-editing
functions, and thus generate many mutants over a rela-
tively short time-period [38]. However, cross-neutralizing
or ‘public’ antibody specificities often appear with the
same kinetics as the so-called ‘private’ neutralizing
antibody response [36], indicating that the virus would
have to be mutating at a rapid rate from the very begin-
ning of the infection. But, in the absence of pressure from
a neutralizing antibody response, the LCMV-glycopro-
tein appears to be resistant to mutations [36]. Geneticwww.sciencedirect.com
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Naive LCMV
Serum electrophoresis of naı¨ve serum and serum 12 days post-LCMV
infection. The gamma-globulin fraction is built of immunoglobulins.reversions of acquired mutations back to wild-type con-
formations have been observed following the removal of
immunological pressure for both LCMV and HIV
[36,39], suggesting that the parental virus strain repre-
sents a state of optimal replication fitness and is likely to
be resistant to the acquisition of ‘unnecessary’ mutations.
One also has to bear in mind that every mutational event
can potentially decrease the replication fitness of the
virus, and might therefore be undesirable. Indeed, experi-
ments in which the rate of viral mutation was dramatically
increased by the co-administration of a chemical mutagen
led to a loss of replication-competent LCMV in vitro [40]
and in vivo [41], a situation termed ‘error catastrophe’.
The rate of viral replication may also influence develop-
ment of a ‘public’ neutralizing antibody response if, for
instance, the presence of high antigen doses favours the
induction of a B cell response [42] generating antibody
cross-reactivity against both parental and escape-mutant
viral strains. In CD8/ mice, both low- and high-dose
LCMV infection results in high viral replication at early
time-points, whereas, wild-type C57BL/6 mice mount
such an effective CTL response that both low- and
high-dose LCMV infection is rapidly controlled. Thus,
a new model was required to directly investigate the
influence of viral replication on the neutralizing antibody
response.
DBA/2 mice contain CD8+ T cells but mount a relatively
weak CTL response, which, in practical terms, means
that low-dose infection of DBA/2 mice is followed by
limited viral replication, whereas high-dose LCMV infec-
tion quickly exhausts CTL function, resulting in a high
level of viral replication [36]. High-dose LCMV infec-
tion of DBA/2 mice results in a phenotype similar to that
observed in CD8/ mice, with virus control occurring
between days 40–60 post-infection and correlating with
the appearance of neutralizing antibodies (Figure 2). In
contrast to CD8/ mice, where neutralizing-escape var-
iants develop in 100% of mice, only 75% of DBA/2 hosts
allow re-emergence of virus in the form of escape variants.
Escape variants from these DBA/2 hosts exhibited amino
acid substitutions in the same region of the viral glyco-
protein as described for variants isolated from CD8/
mice [36]. The remaining 25% of DBA/2 hosts achieved
long-term control of viral replication and developed an
initial neutralizing antibody response that was of a more
‘public’ nature (Figure 2 and [36]). This finding indi-
cated that the cross-neutralizing or ‘public’ nature of the
initial antibody response prevented the development —
or sufficient replication of — escape variants. Interest-
ingly, serum taken from a subset of human patients
infected with HIV also exhibits broad, or cross-reactive,
neutralizing activity when tested against viral isolates
obtained from other patients [18]. Because the DBA/2
experimental model of LCMV infection uses genetically
identical hosts, challenged with the same dose and strainwww.sciencedirect.comof virus, differences that are exhibited by individual mice
(in terms of the repertoire of neutralizing antibodies
produced) suggest that the development of an antibody
response underlies stochastic mechanisms. This is remi-
niscent of the process of affinity maturation, which has
also been reported to be, at least partially, a stochastic
process [43,44]. Thus, it is likely that the development of
a neutralizing antibody response by individual hosts not
only varies considerably [21], but perhaps also reflects a
process of affinity maturation that involves somatic hyper-
mutation. As mentioned previously, low-dose LCMV
infection of DBA/2 mice results in the development of
an effective CD8+ T cell response [36], which limits viral
replication. Strikingly, DBA/2 mice infected with a low
dose of LCMV were found to exhibit a more restricted or
‘private’ neutralizing antibody response [36]. Together,
these observations indicate that the development of a
‘public’ or ‘private’ neutralizing antibody response can be
directly correlated to the level of virus replication.
Hypergammaglobulinemia
As discussed previously, hosts that exhibit long-term
control of LCMV also appear to develop a more cross-
specific or ‘public’ neutralizing antibody response. The
common failure of cross-neutralising antibody formation
can be partially explained by the finding that LCMV and
HIV-specific CD4+ T cell responses (required for the
production of neutralizing IgG [45]) are rapidly energised
in the presence of massive virus replication [46–48].
CD4+ T-cell function might also determine the nature
of the antibody response in another way. LCMV infection
is characterised by an early polyclonal, replication-depen-
dent and CD4+ T cell-dependent, hypergammaglobuli-
nemia [49,50]. By day 12 post-LCMV infection, total
IgG levels are elevated 6–10-fold, and appear as a broad
gammaglobulin peak in serum electrophoresis, suggest-
ing a polyclonal nature (Figure 3). A similar hypergam-
maglobulinemia can be found associated with otherCurrent Opinion in Microbiology 2004, 7:426–433
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malaria [52], HIV [53] and HCV [54].
Cytopathic viral infections are not typically associated
with an increased level of total serum immunoglobulins,
although B-cell responses might be somewhat polyclonal
in nature [49,55]. By contrast, LCMV infection results
in the production of an IgG response in which more than
90% of the total IgG can be said to be non-specific. The
dramatic polyclonal nature of the early IgG response that
is induced by LCMV infection is completely dependent
on the presence of virus-specific CD4+ T cells [50,56]. It
was recently demonstrated that these virus-specific CD4+
T cells recognize LCMV-derived peptides presented by
MHC class II molecules that are present on the surface of
the B cell, despite the majority of stimulated B cells
exhibiting a non-relevant receptor specificity [49].
The biological consequences of this apparent cognate T
helper (Th) cell-dependent polyclonal B-cell response
remain unclear [55]. Antibodies that are protective
against other viral species, for example, VSV, are not
detectable at the peak of the LCMV-induced hypergam-
maglobulinemia (author’s own unpublished data), nor are
antibodies that are capable of neutralizing LCMV. By
contrast, IgG specificities that are directed against certain
auto-antigens and non-related pathogens are detectable
by ELISA [49]. Nevertheless, apparent autoimmune
disease is rarely induced following LCMV infections,
arguing against a direct pathophysiological role for those
autoantibodies detected. CD4+ T cells are required for
development of both the early polyclonal hypergamma-
globulinemia and the later neutralizing antibody
response, however, it remains to be determined whether
subtle alterations in CD4+ T-cell function promote one
type of antibody response over another. Interestingly,
infection of mice lacking SAP (SLAM (signalling lym-
phocyte activation molecule)-associated protein, which is
involved in X-linked lymphoproliferative disease), among
other immunological alterations observed, resulted in
increased activation of CD4+ T cells, correlating with
an impaired LCMV-specific antibody response [57].
Cross-specific antibodies: protection or
disease enhancement?
As discussed, in LCMV infection, the neutralizing anti-
body response can be classified as ‘private’ or ‘public’; the
generation of a public response clearly requiring a high
level of viral replication and appearing to be a stochastic
process. This classification system might be also be
relevant to clinically important infections, such as dengue
virus, where cross-specific antibodies have been found
associated with severe hemorrhagic disease following
secondary infection [57,58]. Although severe disease after
secondary dengue virus infection is a complex process, it
is usually associated with enhanced viremia [59]. Inter-
estingly, dengue cross-specific antibodies can either beCurrent Opinion in Microbiology 2004, 7:426–433cross-protective (early after primary infection [57,60]) or
disease-enhancing, possibly depending on cross-neutraliz-
ing affinity. If cross-neutralizing titers are high enough,
secondary dengue viremia is expected to be lower and
disease milder [60]. However, low cross-neutralizing titers
may enhance dengue virus titers after secondary infection,
due to better virus delivery to macrophages or endothelial
cells via Fc-Receptors (receptor binding IgG antibodies via
the constant domain). Antibody-enhanced virus-replica-
tion, depending on the particular virus studied, seems to
involve not only accelerated delivery via Fc-receptors but
also complement-components, as well as suppression of
cellular antiviral genes by the replication of viruses enter-
ing cells via antibodies [61]. Low cross-neutralizing anti-
body titers could also allow the in vivo formation of dengue
neutralizing antibody-escape mutants [57].
In addition, cross-neutralizing antibodies could poten-
tially provide protection against unrelated pathogens
[62]. Indeed, antibody responses induced by challenge
with Escherichia coli have been shown to provide protec-
tion against Haemophilus influenzae-induced meningitis
[63]. For potential antibody-based HIV vaccines, it will
be important to understand the mechanisms that result in
the formation of broad or cross-neutralizing antibodies,
especially with regard to the rapidly changing neutraliz-
ing epitopes [18]. Conversely, polyclonal B-cell activa-
tion might generate a potentially harmful repertoire of
IgG specificities that could be potentially auto-reactive,
thereby enhancing the risk of auto-immunity or immune
complex disease [64,65]. Autoimmune thrombocytopenia
is a common complication of HIV infection in humans
[66], and antibody-dependent autoimmune haemolytic
anemia has been described following LCMV infection of
some mouse strains [67]. However, autoantibodies follow-
ing HIV infection were not found to be associated with
clinical autoimmune manifestations [68], indicating that
auto-reactive antibodies may often be of a low affinity or
avidity. Another potential biological consequence of poly-
clonal B-cell activation is that non-specific B cells might
compete with virus-specific B cells for space, survival
factors or access to T-cell help. Recent data obtained from
HIV infected patients [53], as well as data obtained from
ongoing LCMV experiments in our laboratory, demon-
strate that competition might well occur between B cells
that bear unrelated or virus-specific specificities.
Conclusions
Dissecting the complex nature of the antibody response
induced by poorly or non-cytopathic viruses is crucial to
our understanding of how to manipulate this response for
the benefit of the host. The exact nature and determinates
of the antibody response — including any requirement for
CD4+ T cells in regulating the ‘private’ versus ‘public’
nature of the response, and the biological consequence of
viral-induced hypergammaglobulinemia — might reveal
novel mechanisms that are used by viruses for immunewww.sciencedirect.com
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particularly important for the generation of new HIV
vaccines that are capable of inducing both protective
CTL and neutralizing-antibody responses.
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